Skip to main content
HCA logo

HCA · HCA Healthcare, Inc.

Track HCA — free
$501.19 -10.59 (-2.07%) At close · Nov 17
Market Cap
$104.69B
Shares
208.89M
Volume · Nov 17 1.24M Avg daily vol (3M) 1.36M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$501.19 Open$506.00 Day$498.06–512.83 52W close$361.32–545.13 Avg vol 30d1.3M Short int4.8M · 2.3% of shares · 3.3d Short vol46% Last earningsOct 27, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Jan 26, 2027 Est · unconfirmed · in 10 wks

Latest documents

2026
Nov 5
Current report 8-K Events of Nov 2
$6,500,000,000 senior notes offering completed

HCA Healthcare’s wholly owned subsidiary completed a $6,500,000,000 public offering of senior notes on November 5, 2026, guaranteed on a senior unsecured basis by HCA Healthcare.

Entered into a material agreement, New debt or off-balance-sheet obligation, Other events Read from the first part of this long document
3 source passages
### Issuance of $6,500,000,000 aggregate principal amount of senior notes On November 5, 2026, HCA Inc. (the “Issuer”), a direct, wholly owned subsidiary of HCA Healthcare, Inc. (the “Parent Guarantor”), completed the public offering of (i) $500,000,000 aggregate principal amount of its 5.200% Senior Notes due 2028 (the “2028 Notes”), (ii) $300,000,000 aggregate principal amount of its Floating Rate Senior Notes due 2028 (the “Floating Rate Notes”), (iii) $1,000,000,000 aggregate principal amount of its 5.350% Senior Notes due 2029 (the “2029 Notes”), (iv) $1,250,000,000 aggregate principal amount of its 5.500% Senior Notes due 2031 (the “2031 Notes”), (v) $1,200,000,000 aggregate principal amount of its 5.750% Senior Notes due 2033 (the “2033 Notes”), (vi) $1,500,000,000 aggregate principal amount of its 6.000% Senior Notes due 2036 (the “2036 Notes”) and (vii) $750,000,000 aggregate principal amount of its 6.500% Senior Notes due 2056 (the “2056 Notes” and, together with the 2028 Notes, the Floating Rate Notes, the 2029 Notes, the 2031 Notes, the 2033 Notes and the 2036 Notes, the “Notes”), each guaranteed on a senior unsecured basis by the Parent Guarantor. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Parent Guarantor. Open the document at this passage
Nov 2
Current report 8-K
Senior notes offering paired with $1.200 billion note redemption

HCA Healthcare, Inc. announced that HCA Inc. proposes a senior unsecured notes offering. HCA Inc. elected to redeem all $1.200 billion of 4.500% senior notes due February 2027 on December 2, 2026, conditioned on receiving offering proceeds.

Other events
2 source passages
On November 2, 2026, HCA Healthcare, Inc. (the “Registrant”) issued a press release (the “Press Release”) announcing the commencement of its proposed public offering by HCA Inc. (the “Issuer”), a direct, wholly owned subsidiary of the Registrant, of senior unsecured notes (the “Offering”). On November 2, 2026, the Issuer provided notice of its election to redeem all $1.200 billion of its 4.500% senior notes due February 2027 (the “Redeemed Notes”). The Redeemed Notes will be redeemed on December 2, 2026 (the “Redemption Date”), conditioned upon the receipt prior to the Redemption Date by the Issuer of the net proceeds from the Offering. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

HCA Healthcare, Inc. reported third-quarter 2026 revenue of $19.849 billion, up 3.6%, while net income attributable to the company declined to $1.579 billion, or $7.27 per diluted share. Uninsured admissions rose 27.2%.

Revenue $19.85B ▲ 3.6% Net income $1.58B ▼ 3.9% Diluted EPS $7.27 ▲ 4.5%
Read from the MD&A section
Oct 27
Earnings call
Q3 2026 earnings call

HCA Healthcare reported adjusted admissions growth of 3%, exchange admissions down approximately 19%, and an approximately $400 million adjusted EBITDA payer-mix headwind. It expects 2026 results in the upper half of guidance ranges and 2027 earnings consistent with 2026.

Oct 27
Current report 8-K
Financial results, Regulation FD disclosure, Other events

HCA Healthcare reported third-quarter revenues of $19.849 billion and Adjusted EBITDA of $3.918 billion, expects full-year operating results in the upper half of 2026 guidance, and declared a quarterly dividend of $0.78 per share.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$78.70B
Trailing 12 months
Net income (TTM)
$6.78B
Trailing 12 months
Revenue growth YoY
+3.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
16.6
Trailing earnings · reciprocal yield 6.0%
FCF yield
5.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$49.59B
Latest balance sheet
Dividend yield
0.6%
Trailing 12 months
Shares change YoY
-8.0%
Year over year · fewer shares
Price change (1Y)
+5.0%
Trailing year
Short interest
2.3%
Latest settlement · 3.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 27, 2026
Q3 FY26

TL;DR. Third-quarter revenue, adjusted EPS, adjusted EBITDA, admissions, emergency-room visits, pricing, cost performance and operating cash flow improved; management expects 2026 results in the upper half of guidance, a $600 million to $800 million incremental Medicaid supplemental-payment benefit, and continued capital returns. Net income and adjusted EBITDA margin declined, payer mix created a $400 million quarterly headwind, surgical volumes fell, and preliminary 2027 earnings are expected to be generally consistent with 2026 as Medicaid supplemental benefits decline by $550 million to $650 million.

Bullish
  • + Cost per equivalent admission excluding Medicaid supplemental payments was essentially flat year over year and improved 40 basis points sequentially.
  • + Management expects full-year 2026 operating results in the upper half of its previously issued guidance ranges.
  • + The full-year 2026 incremental net benefit from Medicaid supplemental-payment programs is now expected to be $600 million to $800 million.
Bearish
  • − The payer-mix shift had an unfavorable impact of approximately $400 million in the third quarter, and the full-year adjusted EBITDA headwind is expected to be at or slightly above the upper end of prior estimates.
  • − Same-facility inpatient surgeries declined 1.4% and outpatient surgeries declined 3.7% year over year.
  • − The preliminary 2027 outlook includes $550 million to $650 million less Medicaid supplemental-payment net benefit, with earnings generally consistent with 2026.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +10%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 76%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +30%
trailing
YTD return +7%
this year
Relative strength +33%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $457 › 200d $445 — 50d above 200d
Institutional flow Distributing
-0% holders QoQ · +143 funds added
Insider flow Distributing
Net -$18.3M over 90 days · 100% sells
Short interest Falling
2.30% of shares out · ▼ -2.1% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,358 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
Revenue growth +7%
Y/Y
EPS growth +29%
Y/Y
Free cash flow $7.7B
Valuation P/E 16.6
in line
Buyback $4.2B
remaining
Balance sheet $45.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 33%
annualized · 1-yr
Max drawdown −34%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed Jul 24, 2026
2026
Revenue Maintained $77B – $79.5B
Jul 14, 2026 $77B – $79.5B changed to Jul 24, 2026 $77B – $79.5B
prior FY $75.6B midpoint +3.5% Y/Y
Adjusted EBITDA Non-GAAP Maintained $15.4B – $16.1B
Jul 14, 2026 $15.4B – $16.1B changed to Jul 24, 2026 $15.4B – $16.1B
Diluted earnings per share Maintained $28.70 – $30.50
Jul 14, 2026 $28.70 – $30.50 changed to Jul 24, 2026 $28.70 – $30.50
prior FY $28.33 midpoint +4.5% Y/Y
Net income attributable to HCA Healthcare $6.3B
next three years
Approved capital expenditures $7B
Previous outlook earlier release · from the Earnings Call filed Mar 31, 2026

Still-open targets the latest release did not restate under the same label.

Same-store volume growth · full year 2% – 3%
Resiliency plan EBITDA · full year $400M
Approved capital projects coming online over the next 24 to 30 m · next 24 to 30 months $5.5B – $6B
Guided vs delivered · last 8 settled
Revenues 2025
guided $75B – $76.5B
$75.6B In line
EPS (diluted) 2025
guided $27.00 – $28.00
$28.33 Beat +3.0%
EPS (diluted) For the Year Ending December 31, 2024
guided $21.60 – $22.80
$22.00 In line
Revenues 2024
guided $67.75B – $70.25B
$70.6B Beat +2.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
76% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $457 › 200d $445 — 50d above 200d
Institutional flow Distributing
-0% holders QoQ · +143 funds added
Insider flow Distributing
Net -$18.3M over 90 days · 100% sells
Short interest Falling
2.30% of shares out · ▼ -2.1% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,358 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $361 Now $501 · 76% Range high $545
vs 200-day avg +13% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HCA
HCA Healthcare, Inc.
this stock
$104.69B +7.4% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.30B +3.1% — — 0.0%
THC
Tenet Healthcare Corp
$22.45B +41.9% +0.9% 8.2 2.2%
EHC
Encompass Health Corp
$13.53B +29.9% +10.5% 21.5 3.7%
FMS
Fresenius Medical Care AG
$11.26B -8.9% +5.9% — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,358
% held
57.9%
Net QoQ
-10.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
871
View
Short & Settlement
Short Interest Falling
Shares short
4.8M
Days to cover
3.3d
Change
-105.1K sh
View
Short Volume
Short vol %
46%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$633.7K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
36.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$18.3M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Buy
Member
Jared Moskowitz
Amount
$1.0K–$15.0K
Traded
Jun 17, 2026
View
Financials
Financials
Revenue (FY)
$75.6B
Net income (FY)
$6.8B
EPS diluted
$28.33
View
Buybacks
Authorized
$10.0B
Remaining
$4.2B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
23

HCA Healthcare’s wholly owned subsidiary completed a $6,500,000,000 public offering of senior notes on November 5, 2026, guaranteed on a senior unsecured basis by HCA Healthcare.

View
Proposed Sales
Value
$903.5K
Shares
1.7K
Filed
Feb 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 27, 2026
View
Investor Relations
Latest news
HCA Healthcare Named a Best Emplo…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
HCA -0.6% +7.6% +30.4% +5.9% +7.4%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +1.7% +12.4% +33.3% +9.0% -0.1%

Capital returns

Latest dividend
$0.78 / share · ex Sep 16, 2026
Declared · upcoming
$0.78 / share · ex Dec 15, 2026
Raised 8.3%
Paid (TTM)
$3.06 / share · 4 payouts
Dividend yield (TTM, derived)
0.61%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$10.00B
Spent (derived)
$5.76B
Remaining
$4.24B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 860730 CUSIP 40412C101 13F (30d) 1298 filings 1193 filers Visit website Investor relations